CDK19

Across TCGA pan-cancer cohorts, CDK19 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CDK19 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher CDK19 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated CDK19 expression acts as an unfavorable survival marker, although some lineages such as LSCC and LUAD show a favorable association.

LSCC, HNSC, and LUAD are the cancer types where CDK19 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	OS	Median	All	0.933	0.697	<.001	44	view →
HNSC	DFS	Median	III,IV	0.538	0.765	.015	8	view →
LUAD	OS	Quartile	All	0.936	0.500	.010	8	view →
PDAC	OS	Median	All	0.282	0.698	.023	7	view →
UCEC	OS	Tertile	All	0.872	0.976	.038	4	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CDK19–LSCC (OS)

Open the LSCC breakdown →